HSPD1 and arthritic joint disease: Our group has focused on the heat shock protein produced by Mycobacterium leprae (hsp65) as a vaccine antigen against several experimental pathologies including TB [20], [28], [36], diabetes [37], arthritis [38], leishmaniasis [39], and cancer in phase I clinical trials [40], [41].